DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lorvotuzumab mertansine
Lorvotuzumab mertansine
The New Generation of Antibody Therapeutics: Current Status and Future Prospects
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
ADC (Antibody-Drug Conjugates
Tanibirumab (CUI C3490677) Add to Cart
Monoclonal Antibodies in Myeloma
Immunotherapy in Multiple Myeloma
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Antibody–Drug Conjugates for Cancer Therapy
INN Working Document 05.179 Update 2011
IMSN Letter on Antibody-Drug Conjugates 2015 03 23
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
INN Working Document 05.179 Update December 2010
(INN) for Biological and Biotechnological Substances
IMGN901 in Hematological Malignancies Protocol #2014-0926 7/16/2015
AHRQ Healthcare Horizon Scanning System – Status Update
A61K9/51 (2006.01) — with International Search Report (Art
Top View
Antibody-Drug Conjugates in Clinical Trials for Lymphoid Malignancies and Multiple Myeloma Bo Yu1 and Delong Liu2,3*
Efficacy Analysis from Phase I Study of Lorvotuzumab
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: a Systematic Review of Agents Under Clinical Development
Antibody Drug Conjugates (ADC)
Monoclonal Antibodies in the Treatment of Multiple Myeloma: Current Status and Future Perspectives
Prescrire Contribution to Proposed INN List
IMSN Open Letter on Antibody-Drug Conjugate 2151012
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Qualifying Therapeutic Discovery Project Grants
Oncology Drugs in the Pipeline
Cancer Immunotherapy Beyond Immune Checkpoint Inhibitors Julian A
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
Ep 3088005 A1
ADC 药物商业化浪潮将至,重点关注平台价值、 021-60338177
[email protected]
联系人 : 许睿 S1480119070016
[email protected]
治疗新突破及外包产业三大核心投资机会
Oncology Drugs in the Pipeline
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
ADC 药物商业化浪潮将至,重点关注平台价值、 021-60338177
[email protected]
联系人 : 许睿 S1480119070016
[email protected]
治疗新突破及外包产业三大核心投资机会